Europe - FRA:ILM1 - DE000A1MMCC8 - Common Stock
The current stock price of ILM1.DE is 14.68 EUR. In the past month the price increased by 11.34%. In the past year, price increased by 3.9%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| AMP.MI | AMPLIFON SPA | 25.66 | 3.08B | ||
| FAGR.BR | FAGRON | 17.5 | 1.52B | ||
| UPR.I | UNIPHAR PLC | 17.73 | 1.01B | ||
| BLC.PA | BASTIDE LE CONFORT MEDICAL | 380 | 196.04M | ||
| VMED.DE | VIROMED MEDICAL AG | N/A | 78.97M |
Medios AG is a holding company, which engages in the provision of pharmaceutical drugs. The company is headquartered in Berlin, Berlin and currently employs 1,006 full-time employees. The firm covers relevant aspects of supply chain like from pharmaceutical supply and manufacture of patient-specific therapies, including blistering and others. The company operates in two segments Pharmaceutical supply which focuses on pharmaceutical wholesale with finished specialty pharma (high-priced drugs for rare and chronic diseases) medications including oncology, neurology, autoimmunology, ophthalmology, infectiology, hemophilia along with offering finished medicinal products; Patient-specific therapies focusing on pharmaceutical manufacturing of patient-specific preparations such as Cytostatic infusions, Antibody therapies, Virostatic and antibiotic medications, Parenteral nutrition solutions, Investigational medicinal products are among others. Its products and services include Patient health & protection and procedures & processes for patient care and digitalization of data.
MEDIOS AG
Heidestrasse 9
Berlin BERLIN DE
Employees: 1006
Phone: 4930232566800
Medios AG is a holding company, which engages in the provision of pharmaceutical drugs. The company is headquartered in Berlin, Berlin and currently employs 1,006 full-time employees. The firm covers relevant aspects of supply chain like from pharmaceutical supply and manufacture of patient-specific therapies, including blistering and others. The company operates in two segments Pharmaceutical supply which focuses on pharmaceutical wholesale with finished specialty pharma (high-priced drugs for rare and chronic diseases) medications including oncology, neurology, autoimmunology, ophthalmology, infectiology, hemophilia along with offering finished medicinal products; Patient-specific therapies focusing on pharmaceutical manufacturing of patient-specific preparations such as Cytostatic infusions, Antibody therapies, Virostatic and antibiotic medications, Parenteral nutrition solutions, Investigational medicinal products are among others. Its products and services include Patient health & protection and procedures & processes for patient care and digitalization of data.
The current stock price of ILM1.DE is 14.68 EUR. The price decreased by -1.61% in the last trading session.
ILM1.DE does not pay a dividend.
ILM1.DE has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
ILM1.DE stock is listed on the Deutsche Boerse Ag exchange.
11 analysts have analysed ILM1.DE and the average price target is 25.11 EUR. This implies a price increase of 71.04% is expected in the next year compared to the current price of 14.68.
MEDIOS AG (ILM1.DE) has a market capitalization of 374.49M EUR. This makes ILM1.DE a Small Cap stock.
ChartMill assigns a technical rating of 5 / 10 to ILM1.DE. When comparing the yearly performance of all stocks, ILM1.DE turns out to be only a medium performer in the overall market: it outperformed 48.13% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to ILM1.DE. While ILM1.DE has a great health rating, there are worries on its profitability.
Over the last trailing twelve months ILM1.DE reported a non-GAAP Earnings per Share(EPS) of 0.74. The EPS increased by 10.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.96% | ||
| ROA | 2.05% | ||
| ROE | 3.6% | ||
| Debt/Equity | 0.33 |
11 analysts have analysed ILM1.DE and the average price target is 25.11 EUR. This implies a price increase of 71.04% is expected in the next year compared to the current price of 14.68.
For the next year, analysts expect an EPS growth of 6.71% and a revenue growth 7.23% for ILM1.DE